Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
DXLK2V
|
||||
| Drug Name |
N-(4-methyl-3-(trifluoromethyl)phenyl)-5-(2-(2-(pyridin-4-yl)ethyl)pyridin-3-yl)-1,3,4-oxadiazol-2-amine
|
||||
| Synonyms |
CHEMBL382218
|
||||
| Indication | Discovery agent | Investigative | [1587926] | ||
| Formula |
C22H18F3N5O
|
||||
| Canonical SMILES |
Cc1ccc(Nc2oc(nn2)c3cccnc3CCc4ccncc4)cc1C(F)(F)F
|
||||
| InChI |
InChI=1S/C22H18F3N5O/c1-14-4-6-16(13-18(14)22(23,24)25)28-21-30-29-20(31-21)17-3-2-10-27-19(17)7-5-15-8-11-26-12-9-15/h2-4,6,8-13H,5,7H2,1H3,(H,28,30)
|
||||
| InChIKey |
TXKJCQVOEAMXER-UHFFFAOYSA-N
|
||||
| Target and Pathway | |||||
| Target(s) | Vascular endothelial growth factor receptor 2 | Target Info | [1587926] | ||
| Vascular endothelial growth factor receptor 1 | Target Info | [1587926] | |||
| KEGG Pathway | Ras signaling pathway | ||||
| Rap1 signaling pathway | |||||
| Cytokine-cytokine receptor interaction | |||||
| Endocytosis | |||||
| PI3K-Akt signaling pathway | |||||
| VEGF signaling pathway | |||||
| Focal adhesion | |||||
| Proteoglycans in cancerhsa04014:Ras signaling pathway | |||||
| HIF-1 signaling pathway | |||||
| Transcriptional misregulation in cancer | |||||
| Rheumatoid arthritis | |||||
| NetPath Pathway | IL2 Signaling Pathway | ||||
| PANTHER Pathway | Angiogenesis | ||||
| VEGF signaling pathway | |||||
| Pathway Interaction Database | HIF-2-alpha transcription factor network | ||||
| Beta3 integrin cell surface interactions | |||||
| Signaling events mediated by TCPTP | |||||
| SHP2 signaling | |||||
| S1P1 pathway | |||||
| VEGF and VEGFR signaling network | |||||
| Integrins in angiogenesis | |||||
| Signaling events mediated by VEGFR1 and VEGFR2 | |||||
| Notch-mediated HES/HEY networkglypican_1pathway:Glypican 1 network | |||||
| S1P3 pathway | |||||
| VEGFR1 specific signals | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.